[HTML][HTML] Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck …
K Klinghammer, T Gauler, A Dietz, V Grünwald… - European Journal of …, 2019 - Elsevier
Background The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the
reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the …
reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the …
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD) …
K Klinghammer, T Gauler, A Dietz… - … journal of cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
Background The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the
reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the …
reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the …
[引用][C] Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck …
K Klinghammer, T Gauler, A Dietz… - … Journal of Cancer, 2019 - ub01.uni-tuebingen.de
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or
metastatic squamous cell carcinoma of the head and neck (CeFCiD) : an open-label phase II …
metastatic squamous cell carcinoma of the head and neck (CeFCiD) : an open-label phase II …
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD) …
K Klinghammer, T Gauler, A Dietz… - European Journal of …, 2019 - europepmc.org
BACKGROUND: The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is
the reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of …
the reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of …
[引用][C] Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck …
K Klinghammer, T Gauler, A Dietz… - European …, 2019 - tobias-lib.ub.uni-tuebingen.de
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or
metastatic squamous cell carcinoma of the head and neck (CeFCiD) : an open-label phase II …
metastatic squamous cell carcinoma of the head and neck (CeFCiD) : an open-label phase II …
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD) …
K Klinghammer, T Gauler, A Dietz… - European Journal of …, 2019 - ejcancer.com
Background The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the
reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the …
reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the …